WO2008015383A3 - Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer - Google Patents

Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer Download PDF

Info

Publication number
WO2008015383A3
WO2008015383A3 PCT/GB2007/002755 GB2007002755W WO2008015383A3 WO 2008015383 A3 WO2008015383 A3 WO 2008015383A3 GB 2007002755 W GB2007002755 W GB 2007002755W WO 2008015383 A3 WO2008015383 A3 WO 2008015383A3
Authority
WO
WIPO (PCT)
Prior art keywords
bmp
breast
prostate cancer
cancer therapies
therapies
Prior art date
Application number
PCT/GB2007/002755
Other languages
English (en)
Other versions
WO2008015383A8 (fr
WO2008015383A2 (fr
Inventor
Wen Guo Jiang
Original Assignee
Univ Cardiff
Wen Guo Jiang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff, Wen Guo Jiang filed Critical Univ Cardiff
Publication of WO2008015383A2 publication Critical patent/WO2008015383A2/fr
Publication of WO2008015383A3 publication Critical patent/WO2008015383A3/fr
Publication of WO2008015383A8 publication Critical patent/WO2008015383A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne le rôle des protéines BMP-9 et/ou BMP-10 dans le traitement du cancer du sein ou de la prostate.
PCT/GB2007/002755 2006-07-29 2007-07-20 Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer WO2008015383A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0615129.4 2006-07-29
GBGB0615129.4A GB0615129D0 (en) 2006-07-29 2006-07-29 Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies

Publications (3)

Publication Number Publication Date
WO2008015383A2 WO2008015383A2 (fr) 2008-02-07
WO2008015383A3 true WO2008015383A3 (fr) 2008-08-14
WO2008015383A8 WO2008015383A8 (fr) 2009-07-16

Family

ID=37006438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002755 WO2008015383A2 (fr) 2006-07-29 2007-07-20 Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer

Country Status (2)

Country Link
GB (1) GB0615129D0 (fr)
WO (1) WO2008015383A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332977B1 (fr) 2004-07-23 2015-11-25 Acceleron Pharma Inc. Polypeptides du récepteur AvtRII
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
DK1973559T3 (da) 2005-11-23 2013-03-25 Acceleron Pharma Inc Activin-ActRIIa antagonister samt anvendelser til fremme af knoglevækst
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN103920139B (zh) 2007-02-01 2018-02-02 阿塞勒隆制药公司 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI459963B (zh) 2007-02-09 2014-11-11 Acceleron Pharma Inc 包含ActRIIa-Fc融合蛋白的醫藥組合物；ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途；ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
WO2009084739A1 (fr) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp10
WO2009084738A1 (fr) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp9
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
EP2440576A4 (fr) 2009-06-08 2013-11-20 Acceleron Pharma Inc Procédé visant à augmenter le nombre d'adipocytes thermogènes
KR20210034684A (ko) 2009-06-12 2021-03-30 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
EP2501400B1 (fr) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Protéines actriib et variants et utilisations de celles-ci se rapportant à l'induction de l'utrophine pour une thérapie de la dystrophie musculaire
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
KR102279522B1 (ko) 2012-11-02 2021-07-19 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
EP3154566B1 (fr) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
HUE062189T2 (hu) 2014-12-03 2023-09-28 Celgene Corp Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
US11578110B2 (en) 2015-08-25 2023-02-14 Histide Ag Compounds for inducing tissue formation and uses thereof
EP3998076A1 (fr) * 2015-09-17 2022-05-18 Histide AG Association pharmaceutique d'agoniste de recepteur de facteur de croissance et d'inhibiteur de proteine d'adhesion pour convertir une cellule neoplastique en cellule non-neoplastique, et ses utilisations
SI3349776T1 (sl) * 2015-09-17 2021-04-30 Histide Ag Farmacevtska asociacija agonista receptorja rastnega faktorja in zaviralca adhezijskega proteina za pretvorbo neoplastične celice v ne-neoplastično celico in njena uporaba
WO2023069447A1 (fr) * 2021-10-18 2023-04-27 The Uab Research Foundation Bmp9 ou agoniste de celui-ci et ses utilisations en rapport avec la réduction des métastases du cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435243A2 (fr) * 1998-11-13 2004-07-07 Curis, Inc. Procédés servant à soulager les symptomes du cancer
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
WO2006029406A2 (fr) * 2004-09-09 2006-03-16 Stryker Corporation Methodes de traitement de tumeurs osseuses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435243A2 (fr) * 1998-11-13 2004-07-07 Curis, Inc. Procédés servant à soulager les symptomes du cancer
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
WO2006029406A2 (fr) * 2004-09-09 2006-03-16 Stryker Corporation Methodes de traitement de tumeurs osseuses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 11 March 2004 (2004-03-11), ROSEN C.A. ET AL.: "New albumin fusion proteins useful for preparing a composition for treating diabetes mellitus", XP002474103, retrieved from WWW.EBI.AC.UK accession no. ADH22105 *
SONG J.J. ET AL.: "Bone morphogentic protein-9 binds to liver cells and stimulates proliferation.", ENDOCRINOLOGY, vol. 136, no. 10, 1995, pages 4293 - 4297, XP002474102 *
VARADY P. ET AL.: "Morphologic analysis of BMP-9 gene therapy induced osteogenesis.", HUMAN GENE THERAPY, vol. 12, 10 April 2001 (2001-04-10), pages 697 - 710, XP002474101 *

Also Published As

Publication number Publication date
WO2008015383A8 (fr) 2009-07-16
WO2008015383A2 (fr) 2008-02-07
GB0615129D0 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
WO2008015383A3 (fr) Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer
IL184617A0 (en) Dr5 antibodies and uses thereof
WO2007127010A3 (fr) Composés de diarylthiohydantoïne
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
MX2019015200A (es) Compuestos de diarilhidantoina.
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
EP2173740A4 (fr) Inhibiteurs de l'hème-oxygénase et leur utilisation dans le traitement du cancer et de maladies du système nerveux central
HK1170485A1 (zh) -噻唑烷- -酮衍生物及其在癌症治療中的用途
WO2009053041A3 (fr) Identification de marqueurs associés aux tumeurs à des fins de diagnostic et de thérapie
WO2008089397A3 (fr) Marqueurs du cancer adrb2
WO2009013543A3 (fr) Agents de liaisons ciblés dirigés vers kdr, et utilisations de ceux-ci - 035
WO2008150530A3 (fr) Molécules de liaison de cripto
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2007100920A3 (fr) Diagnostic et traitement du cancer de la prostate
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
MX2012001513A (es) Uso de melanocortinas para tratar la dislipidemia.
ZA200709542B (en) Combination therapy in the treatment of cancer
WO2009074253A3 (fr) Dérivés de phospholipide de clofarabine
WO2009046123A3 (fr) Antagonistes de nlrr-1 et leurs utilisations
WO2008061048A3 (fr) Procédés et compositions permettant de diagnostiquer et de traiter le cancer de la prostate
WO2008009895A3 (fr) Matriptase-2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766318

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766318

Country of ref document: EP

Kind code of ref document: A2